Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection

BACKGROUND: In phase 3 MODIFY I/II trials, bezlotoxumab significantly reduced recurrence of Clostridioides (Clostridium) difficile infection (rCDI) over 12 weeks. Choice of CDI antibacterial treatment may affect CDI-related outcomes; therefore, this prespecified analysis assessed if the magnitude of...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubberke, Erik R, Gerding, Dale N, Kelly, Ciarán P, Garey, Kevin W, Rahav, Galia, Mosley, Audrey, Tipping, Robert, Dorr, Mary Beth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264839/
https://www.ncbi.nlm.nih.gov/pubmed/32523972
http://dx.doi.org/10.1093/ofid/ofaa157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264839/
https://www.ncbi.nlm.nih.gov/pubmed/32523972
http://dx.doi.org/10.1093/ofid/ofaa157

Ejemplares similares